给药途径
|
TD, IM, IV, oral, sublingual, buccal
|
生物利用度
|
92% (transdermal) 89% (intranasal) 50% (buccal) 33% (ingestion)
|
依赖倾向
|
Moderate - High
|
排泄
|
60% Urinary (metabolites, <10% unchanged drug)
|
半衰期
|
(IV)= 2.5 minutes Intranasal = 6.5 mins Transdermal = 7 hours (range 3–12 h)
|
法定药品分级
|
Class A (UK)
|
法定药品分级
|
Schedule II (US)
|
代谢
|
hepatic, primarily by CYP3A4
|
妊娠期药物分类
|
C (US)
|
蛋白结合率
|
80-85%
|
熔点
|
87.5°C (189.5°F)
|